Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CELUW vs CELU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CELU Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–0 Matrix Metrics)

CELU Overall Winner 6-Pillar Tally: CELUW 0 – 5 CELU (1 Tie) Matrix Metrics: CELUW 0 – 7 CELU

As of Nov 20, 2026, Celularity Inc. (CELU) is the stronger overall head-to-head candidate over CELUW (CELUW) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CELUW carries a Unified Composite Score of 41.3/100 (SELL) at $0.00 (N/M Forward P/E, N/A operating margin), whereas CELU carries 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin).

  • Technical & Structure Timing Caution: CELUW is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.5); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CELUW vs CELU
CELUW US Equity
CELUW
Institutional Equity
$0.00
+533.33% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.52β · 2163% Vol
Unified Composite Score
41.3 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -36.3%), weak momentum, RSI 43
RSI-14: 42.5 · SMA20: $0.00 · SMA50: $0.01
CELU NASDAQ Head-to-Head Winner
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
TTM Revenue $19M
Forward P/E N/M
Beta / 30D Vol 2.01β · 135% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.71 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (CELUW 0 – 5 CELU)

Columns: Metric · CELUW · CELU
1. Valuation Multiples CELU
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 2.7x
2. Growth & Scale CELU
Revenue Growth (YoY) N/A -5.3%
Earnings Growth (YoY) N/A -61.3%
TTM Revenue (USD) N/A $19M
Market Cap N/A $15.2M
3. Profitability & Quality CELU
Gross Margin N/A 19.2%
Operating Margin N/A -254.0%
Net Profit Margin N/A -245.7%
Return on Equity (ROE) N/A -6367.2%
4. Balance Sheet & Cash Flow CELU
Cash Generation (TTM) N/A -$8.9M
Cash Flow Margin N/A -47.8%
Net Cash / Leverage N/A ROE $35M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CELU
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 116.6% (50th %ile)
Put/Call OI Skew N/A 3.60x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CELUW (0) vs CELU (7)
Institutional Metric CELUW CELU Criterion Row Edge
Market Capitalization
Scale
N/A $15.2M Larger Scale CELU
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -5.3% Higher Growth CELU
Operating Margin (TTM)
Profitability
N/A -254.0% Higher Margin CELU
Net Profit Margin
Profitability
N/A -245.7% Higher Margin CELU
Return on Equity (ROE)
Capital Efficiency
N/A -6367.2% Higher ROE CELU
52-Week Range Position
Momentum
2% ($0–$0) 2% ($0–$3) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.52β · 2163% Vol 2.01β · 135% Vol Lower Realized Risk CELU
Unified Institutional Score
Composite Signal
41.3 / 100 (SELL) 42.9 / 100 (HOLD) Higher Composite CELU
Trailing 12M Revenue (USD)
Operating Scale
N/A $19M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 19.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$8.9M ($35M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CELU +68.09 pp
CELUW: -54.76% · CELU: +13.33%
3M Horizon CELU +41.72 pp
CELUW: -79.79% · CELU: -38.07%
6M Horizon CELU +38.97 pp
CELUW: -92.8% · CELU: -53.83%
1Y Horizon CELU +38.97 pp
CELUW: -92.8% · CELU: -53.83%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CELUW vs CELU. Trailing 12-month operating profitability (CELUW N/A vs CELU -254.0%) and valuation multiples (CELUW N/M vs CELU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CELUW ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CELU ADR TTM Benchmark FX-Normalized USD
TTM Revenue$19M
Gross Margin19.2%
Op. Margin-254.0%
ROE / Fwd P/E-6367.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CELUW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CELUW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CELU BREAKDOWN
60d in phase · OBV NEUTRAL
Current IV 116.6%
IV Percentile 50th %ile
Put/Call OI Skew 3.60x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CELU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CELUW Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CELU Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.2M market capitalization and -254.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CELUW vs CELU Key Questions & Quantitative Answers

As of Nov 20, 2026, Celularity Inc. (CELU) is the stronger overall head-to-head candidate over CELUW (CELUW) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CELUW carries a Unified Composite Score of 41.3/100 (SELL) at $0.00 (N/M Forward P/E, N/A operating margin), whereas CELU carries 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin). Technical & Structure Timing Caution: CELUW is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.5); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CELU leads the Growth & Scale pillar: CELUW posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CELU at -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin). On trailing 12-month operating scale, CELUW generates N/A in USD-normalized revenue versus $19M for CELU. In operating R&D and SG&A reinvestment, CELUW deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CELU.

CELU screens cheaper on headline valuation multiples. CELUW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CELUW (N/A ROE) versus CELU (-6367.2% ROE) capital efficiency.

In options market volatility and institutional positioning, CELUW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 2163% Vol realized risk). By comparison, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.